CAMBRIDGE, Mass., April 18, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming investor conferences:
Chardan's 7th Annual Genetic Medicines & Cell Therapy Manufacturing Virtual Summit
Fireside Chat: Monday, April 24, 2023 at 9:30 am ET
H.C. Wainwright BioConnect Investor Conference
Fireside Chat: Tuesday, May 2, 2023 at 12:00 pm ET
Location: Nasdaq World Headquarters, New York, NY
The JMP Securities Life Sciences Conference
Fireside Chat: Tuesday, May 16, 2023 at 3:00 pm ET
Location: New York Hilton Midtown, New York, NY
A live webcast and archived replay of the fireside chats will be available on the investors section of our website, linked here: https://ir.vorbio.com/events-presentations/
About Vor Bio
Vor Bio is a clinical-stage cell and genome engineering company that aims to change the standard of care for patients with blood cancers by engineering hematopoietic stem cells to enable targeted therapies post-transplant. For more information, visit: www.vorbio.com.
Contact:
Investors & Media
Sarah Spencer
+1 857-242-6076
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$0.87 |
| Daily Change: | -0.02 -2.22 |
| Daily Volume: | 238,730 |
| Market Cap: | US$59.540M |
September 05, 2024 | |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
